相关实验视频
Updated: Jan 15, 2026

Electrocardiogram Recordings in Anesthetized Mice using Lead II
Published on: June 20, 2020
评估QT间隔延长使用Iptacopan的度-QT建模,一个口服补充因子B抑制剂,在健康个体中的QT延长
Noemi Kaetterer1, Kenneth Kulmatycki2, Prasanna Kumar Nidamarthy3
1BioMedical Research, Novartis Pharma AG, Basel, Switzerland.
口服B因子抑制剂伊普塔科潘在健康人群中没有表现出心脏QT延长或心律不整的潜在风险,仅用一次性,超治疗剂量. 安全性和耐受性在第一阶段研究中得到证实.
科学领域:
- 药理学 药理学是指药理学的学科.
- 心脏病学 心脏病学
- 药品安全 药品安全
背景情况:
- 伊普塔科潘是一种口服,选择性,可逆的小分子B因子抑制剂.
- 评估心脏安全性,特别是QT间隔延长,对于药物开发至关重要.
研究的目的:
- 为了评估单次,超治疗性口服剂量伊普塔科潘的心脏和安全参数.
- 评估伊普塔科潘对弗里德里西亚校正的QT间隔 (QTcF) 和其前节律潜在的影响.
主要方法:
- 一个第一阶段,单次上升剂量 (SAD) 研究 (A2107) 在健康参与者中进行.
- 参与者接受了单次,超治疗性口服剂量的伊普塔科班 (400,800或1200毫克) 或安慰剂.
- 在集成数据集中分析了QTcF与先前的首次人体研究 (X2101) 的数据集.
主要成果:
- 估计与安慰剂调整后,QTcF与基线的变化在所有Iptacopan剂量中都是最小的.
- 没有观察到统计学意义上的QT延长,这表明单次,超治疗剂量没有风险.
- 伊普塔科潘的耐受性很好,没有严重的不良事件或因不良事件而停止治疗.
结论:
- 在健康个体中,单次,超治疗性口服剂量的伊普塔科班不会延长QTcF间隔.
- 伊普塔科潘没有表现出任何前节律失常的潜力,并且耐受性很好,支持其安全性.
更多相关视频
07:35Assessment of Open Probability of the Mitochondrial Permeability Transition Pore in the Setting of Coenzyme Q Excess
Published on: June 1, 2022
08:28Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus
Published on: April 5, 2011
相关概念视频
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
Compartment Models: Two-Compartment Model
Drug Concentration Versus Time Correlation
Two pivotal parameters are the minimum effective concentration (MEC) and the minimum toxic concentration (MTC). The MEC is the...
One-Compartment Open Model for IV Bolus Administration: General Considerations
The drug's presence in the body is defined by an equation representing the difference between the rates of drug entry and exit. Key parameters—elimination rate constant,...
Noncompartmental Analysis: Miscellaneous Pharmacokinetic Parameters
One key aspect of the noncompartmental approach is determining a drug's total clearance. This can be done by dividing the drug dose by the area under the concentration-time curve from zero to infinity. The area under the concentration-time curve represents the drug's...
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...